Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Berenberg Bank Upgrades Grifols (NASDAQ:GRFS) to Strong-Buy | 30 | MarketBeat | ||
Di | Grifols' pediatric bleeding control solution gets FDA nod | 23 | Investing.com | ||
Di | Brookfield fund delays Grifols takeover bid for second time after failing to raise required €10,000 million | 37 | thecorner.eu | ||
Mo | Grifols falls on report Brookfield delays offer on funding issues | 38 | Seeking Alpha | ||
22.10. | Grifols, BARDA Partner to Test Eye Drops to Treat Mustard Gas Injury | 6 | Contract Pharma | ||
22.10. | Grifols kooperiert mit BARDA bei Behandlung von Schwefellost-Augenschäden | 3 | Investing.com Deutsch | ||
22.10. | Grifols partners with BARDA on sulfur mustard eye treatment | 4 | Investing.com | ||
01.10. | Brookfield fund asks Grifols for more time to analyse takeover bid and complicates bidding process | 41 | thecorner.eu | ||
30.09. | Brookfield asks for more time to weigh potential Grifols deal - report | 22 | Seeking Alpha | ||
30.09. | Brookfield to Request More Time for Grifols Due Diligence | 32 | BNN Bloomberg | ||
30.09. | Grifols plans to invest $402 million in new industrial centre, El Economista says | 21 | Reuters | ||
26.09. | CNMV issues warning to Grifols, Gotham and General Industrial Partners fund for very serious breaches of law | 40 | thecorner.eu | ||
25.09. | Spain's CNMV sanctions Grifols and short-seller Gotham City | 43 | Reuters | ||
23.09. | Grifols SA - 6-K, Report of foreign issuer | 21 | SEC Filings | ||
23.09. | Brookfield fund extends study process for another month to decide whether to present takeover bid for Grifols | 34 | thecorner.eu | ||
23.09. | Grifols Accelerates Plan to Cut Chairman's Executive Powers | 27 | BNN Bloomberg | ||
23.09. | Group of funds ask for seat on board to be able to monitor Brookfield's possible takeover bid for Grifols | 10 | thecorner.eu | ||
23.09. | GRIFOLS, S.A.: The Board of Directors of Grifols has resolved that Mr. Thomas Glanzmann becomes non-executive Chairman. | 9 | CNMV | ||
20.09. | Grifols minority shareholders team up to ask for a board seat | 19 | Reuters | ||
19.09. | Grifols Investor Group With 7.7% Holding Seeks Seat on Board | 15 | BNN Bloomberg |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MERCK KGAA | 154,05 | +1,35 % | JEFFERIES stuft MERCK KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA mit einem Kursziel von 180 Euro auf "Buy" belassen. Analyst Brian Balchin wird in seinem am Dienstag vorliegenden... ► Artikel lesen | |
GSK | 17,140 | +2,05 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1550 Pence auf "Underweight" belassen. Die Briten hätten die Erwartungen umsatzseitig erfüllt und... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 436,60 | +0,47 % | Vertex Aktie: Was können Sie jetzt erwarten? | Die Vertex Pharmaceuticals-Aktie verzeichnete am 31. Oktober 2024 einen leichten Kursanstieg von 1,84% auf 438,53 Euro. Trotz der positiven Kursentwicklung in den letzten Wochen, mit einem Zuwachs von... ► Artikel lesen | |
BAUSCH HEALTH | 9,002 | -0,33 % | Bausch Health Companies Inc.: Bausch Health Announces Third Quarter 2024 Results | Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 254,50 | +0,71 % | Alnylam Pharmaceuticals Inc. Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):Earnings: -$111.57 million in Q3 vs. $147.75 million in the same period last year.
EPS: -$0.87... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 1,125 | -0,53 % | Nektar Therapeutics: Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia | - Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) -
- Eight of nine patients achieved complete remission... ► Artikel lesen | |
APONTIS PHARMA | 9,720 | -0,41 % | APONTIS PHARMA: Annahme des öffentlichen Übernahmeangebots von Zentiva empfohlen | Vorstand und Aufsichtsrat der APONTIS PHARMA AG, einem führenden deutschen Anbieter von Single Pill-Kombinationen, haben heute eine gemeinsame Stellungnahme zum öffentlichen Übernahmeangebot der Zentiva... ► Artikel lesen | |
MEDPACE | 296,00 | +0,27 % | Medpace Holdings, Inc. Reports Third Quarter 2024 Results | CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Revenue... ► Artikel lesen | |
CANTOURAGE GROUP | 4,620 | +0,87 % | Original-Research: Cantourage Group SE (von Montega AG): Kaufen | Original-Research: Cantourage Group SE - von Montega AG 16.10.2024 / 17:25 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | 0,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. | NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the... ► Artikel lesen | |
SCYNEXIS | 1,248 | -0,24 % | SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to... ► Artikel lesen | |
INVENTIVA | 2,455 | -1,01 % | INVENTIVA: Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH | The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on... ► Artikel lesen | |
CHAMPIONS ONCOLOGY | 3,480 | -0,57 % | CHAMPIONS ONCOLOGY, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
GABATHER | 0,035 | -15,53 % | Nasdaq Stockholm AB: New equity right for trading, Gabather TO 6 | At the request of Gabather AB, equity rights TO 6 will be traded on First North
Growth Market as from 5 September 2024.
Security name: Gabather TO 6
-----------------------------
Short name: GABA... ► Artikel lesen | |
BAYER | 25,100 | +1,23 % | Aktie von Bayer läuft heute schlechter (25,62 €) | Im Minus liegt zur Stunde die Aktie von Bayer . Das Papier kostete zuletzt 25,62 Euro. Am Aktienmarkt liegt das Wertpapier von Bayer derzeit im Minus. Das Wertpapier verbilligte sich um 13 Cent. Gegenwärtig... ► Artikel lesen |